Predict your next investment

Venture Capital
biossom.com.cn

See what CB Insights has to offer

Investments

11

Portfolio Exits

2

About Biossom Investment Management

Biossom Investment Management is a venture capital fund that focuses on investments in the bio-pharmaceuticals industry.

Biossom Investment Management Headquarter Location

5th Floor, Building 2, Aipuyi Building No. 1, Disheng East Road, Beijing Economic and Technological Development Zone

Beijing, Beijing, 100176,

China

+86 010-59773801

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Biossom Investment Management News

China: CANBridge $25m Series B; VoxelCloud $10m Series A; Huajiao Live Video $14m funding

May 24, 2017

CANBridge Life Sciences, VoxelCloud and Huajiao Live Video have closed funding rounds. CANbridge Life Sciences raises $25m Series B CANbridge Life Sciences , a Beijing, China-based clinical-stage bio-pharmaceutical company focused on developing Western drug candidates in China and North Asia, has closed a $25 million Series B round led by Lapam Capital , with participation from Qiming Venture Partners , Yuanming Capital , Yanyuan Capital, Biossom Investment Management and Wuxi AppTec . The company, which has raised over $40 million across Series A and B financing rounds in total, has plans for additional strategic transactions in 2017. It intends to use the funds for the clinical trial development of its two lead compounds, CAN008 and CAN017, in China. CAN008, a fully-human fusion onco-immunotherapy, is currently in a Phase I/II for the treatment of glioblastoma multiforme (GBM), in Taiwan. CANbridge plans to initiate a Phase II CAN008 GBM trial in China in 2018. CAN017, an antibody inhibitory onco-immunotherpy, will target esophageal squamous cell cancer (ESCC), the prevalent form of oesophagal cancer in Asia. Led by James Xue, PhD, Chairman and CEO, CANbridge is a clinical stage biopharmaceutical company accelerating development and commercialisation of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). Sequoia Capital leads $10m Series A in VoxelCloud Sequoia Capital has led a $10 million series A round in Los Angeles-based AI startup VoxelCloud , which maintains research teams in Shanghai and Suzhou. VoxelCloud provides automated medical image analysis services. VoxelCloud was founded in 2015 by the team Demetri Terzopoulos, Liang Jianming, and Ding Xiaowei. It previously raised $5.5 millon in an angel round in September 2016. Proceeds from this Series A round will expand its cope of medical image analysis services, and establish further collaboration with medical institutions in China and the US. In an official statement, a Sequoia representative said, “We have long believed in the vast potential of artificial intelligence in medicine. Our partnership with VoxelCloud is driven by this vision. We are excited to witness this innovation and be part of it through our investment in VoxelCloud.” The company makes use of AI and cloud-computing technology to provide personalised medical image analysis by building medical image knowledge graph based on medical semantics and multiple artificial intelligence models. Its products have provided end-to-end solutions for lung cancer, diabetic retinopathy, coronary heart disease and liver disease. Tian Ge Interactive invests $14m in Huajiao Live Video Hong Kong-listed Tian Ge Interactive Holdings Ltd., a Hangzhou-based live social video platform, have made an RMB100 million ($14 million) investment in Huajiao Live Video, a live video streaming mobile app backed by Qihoo 360 Technology Co. Ltd. The transaction also sees the two companies forming a strategic partnership for a term of two years to develop their live video streaming business, advanced technology, business model and online live streaming product. This will see Tian Ge participate in the research, operation, and marketing of Huajiao Live Video. Officially launched in 2015, Huajiao raised RMB300 million ($45 million) in a series A round from Chinese state-owned entity Zhongshoujian, with Qihoo 360 injecting RMB60 million ($8 million). Also Read:

Biossom Investment Management Investments

11 Investments

Biossom Investment Management has made 11 investments. Their latest investment was in Pharmcube as part of their Series A - II on September 9, 2018.

CBI Logo

Biossom Investment Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/17/2018

Series A - II

Pharmcube

Yes

1

8/3/2018

Series B

YunMed

Yes

1

4/11/2018

Series A

ImmuneOnco Biopharma

$15.95M

Yes

2

1/31/2018

Series D

Subscribe to see more

Subscribe to see more

10

1/31/2018

Series E

Subscribe to see more

Subscribe to see more

10

Date

9/17/2018

8/3/2018

4/11/2018

1/31/2018

1/31/2018

Round

Series A - II

Series B

Series A

Series D

Series E

Company

Pharmcube

YunMed

ImmuneOnco Biopharma

Subscribe to see more

Subscribe to see more

Amount

$15.95M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Biossom Investment Management Portfolio Exits

2 Portfolio Exits

Biossom Investment Management has 2 portfolio exits. Their latest portfolio exit was CANbridge Life Sciences on December 10, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/10/2021

IPO

$99M

1

6/19/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/10/2021

6/19/2020

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.